BIRC5 and breast cancer: It demonstrated a significantly worse 5-year survival prognosis in association with the higher BIRC5/survivin levels within each cohort (hazard ratio (HR) 1.12 [1.03–1.57], p = 0.028 for VGR-BC, HR 1.62 [1.33–1.98], p < 0.0001 for SCAN-B, HR 2.15 [1.78–2.60], p < 0.0001 for METABRIC) (Figure 1C).